A5032129717- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Rabies epidemiology and control
- Viral Infections and Vectors
- Microbial infections and disease research
- COVID-19 Clinical Research Studies
- Cutaneous lymphoproliferative disorders research
- Gastrointestinal Tumor Research and Treatment
- Long-Term Effects of COVID-19
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Venous Thromboembolism Diagnosis and Management
- T-cell and Retrovirus Studies
University Hospitals Sussex NHS Foundation Trust
2019-2020
Nelson Hospital
2019
University of Otago
2019
Nelson Marlborough Institute of Technology
2019
Royal Sussex County Hospital
2019
King's College London
2016
A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or complication inflammation, is emerging in literature. Data on incidence venous thromboembolism (VTE) are extremely limited.
Background: Ibrutinib is a Bruton's tyrosine-kinase (BTK) inhibitor that approved as second-line treatment in chronic lymphocytic leukemia (CLL).While recent trials have demonstrated impressive results for ibrutinib, there remains paucity of real-world data on its use the clinical setting.Methods: In this single-center study carried out at Brighton and Sussex University Hospitals, we retrospectively compared outcomes 38 patients with relapsed CLL who received ibrutinib versus those...
<h3>Introduction</h3> Clinical trials of pirfenidone and nintedanib have shown similar reduced rates lung function decline in patients with idiopathic pulmonary fibrosis (IPF). In 2013 NICE approved for use IPF forced vital capacity (FVC) between 50% 80% predicted. More recently, has been available on an individual patient supply program (IPSP). <h3>Aims</h3> Reporting early experience two tertiary referral centres, focussing characterising the treated population, assessing indications use,...